



Examiner: Julie K. Staples

Art Unit: 1813

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 	• •	rr	سربيد	 	•	

In re Application of:

LAWRENCE TAMARKIN ET AL.

Serial No. 08/215,030

Filed: March 18, 1994

For: COMPOSITION AND METHOD FOR REDUCING TOXICITY OF

BIOLOGICALLY-ACTIVE FACTORS

RESPONSE

Assistant Commissioner of Patents Washington, DC 20231

Sir:

RECEIVED

NAY 0 2 1995

GROUP 1800

Responsive to the election requirement dated November 23, 1994, a response to which is due April 24, 1995, applicants respectfully request reconsideration of the above-identified application in view of the following election.

Election of Species Under 35 U.S.C. § 121

The Examiner stated that an election of species would be required as it was found that claims 9, 16, and 20 are generic to a plurality of patentably distinct species. Accordingly, pursuant to 35 U.S.C. § 121, one of the following species must be elected:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231, on April 20, 1995.

Roxanne Edwards Cenatempo - Reg. No. 38,767



Species 1: Interleukin 2(IL-2)

Species 2: lipid A

Species 3: phospholipase A2

Species 4: endotoxins

Species 5: Staphylococcal enterotoxin B

Species 6: Type I Interferon

Species 7: Type II Interferon

Species 8: Tumor Necrosis Factor

Species 9: IL-1

Species 10: IL-6

Species 11: IL-8

Species 12: IL-4

Species 13: Transforming Growth Factor-B

Species 14: Lymphotoxin

Species 15: IL-5

Species 16: Migration Inhibition Factor

Species 17: IL-3

Species 18: Granulocyte-Macrophage Colony-Stimulating Factor (CSF)

Species 19: Monocyte- Macrophage CSF

Species 20: Granulocyte CSF

Species 21: IL-7

Species 22: IL-10

Species 23: IL-11

Species 24: IL-12

Species 25: IL-13

Species 26: Vascular Ephithelial Growth Factor (VEGF)

Serial No. 08/215,030 RESPONSE

Species 27: Agiogenin

Species 28: Transforming Growth Factor (TGFα)

Species 29: Heat shock proteins

Species 30: Carbohydrate moieties of blood groups

Species 31: Rh factors

Species 32: Fibroblast Growth Factor

Applicants elect Species 1, namely Interleukin 2 (IL-2) for further prosecution.

The Examiner stated that along with an identification of the species that is elected for further prosecution, applicants must also provide a list of all claims readable thereon, including any claims subsequently added.

Accordingly, applicants submit that all of the pending claims read on Species 1, namely, Interleukin 2 (IL-2).

It is respectfully submitted that the foregoing is completely responsive to the election requirement mailed November 23, 1994, and that all claims remaining in the application are in condition for allowance. Such action is courteously solicited.

If the Examiner believes that any other informalities remain in the case which may be corrected by Examiner's amendment, or that there are any other issues which can be resolved by a telephone interview, a telephone call to the undersigned attorney at (404) 818-3700 is respectfully solicited.

Respectfully submitted,

JONES & ASKEW

By: Róxanne Edwards Cenatempo

enatempo

Reg. No. 38,767

191 Peachtree Street, N.E. 37th Floor Atlanta, GA 30303 (404) 818-3700

Our Docket: 01994-0021